Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors

Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding

(2019) Sofia Gkountela et al.   CELL

Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma

(2019) Sabine Riethdorf et al.   CLINICAL CHEMISTRY

Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets

(2019) Arutha Kulasinghe et al.   Cancers

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer

(2019) Yang Wang et al.   Scientific Reports

Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status

(2019) Joseph W. Po et al.   PLoS One

Neutrophils escort circulating tumour cells to enable cell cycle progression

(2019) Barbara Maria Szczerba et al.   NATURE

Heterogeneous expression of programmed death receptor-ligand 1 on circulating tumor cells in patients with lung cancer

(2019) Yasuhiro Koh et al.   Clinical Lung Cancer

Clinical applications of the CellSearch platform in cancer patients

(2018) Sabine Riethdorf et al.   ADVANCED DRUG DELIVERY REVIEWS

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, andKRASPoint Mutations in Circulating Tumor Cells

(2018) Amin El-Heliebi et al.   CLINICAL CHEMISTRY

Circulating tumor cells count as a predictor of survival in lung cancer

(2018) Konstantinos Syrigos et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

(2018) Ming Sound Tsao et al.   Journal of Thoracic Oncology

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab

(2018) Nicolas Guibert et al.   LUNG CANCER

KRAS -Mutant Non-Small Cell Lung Cancer: From Biology to Therapy

(2018) Irene Ferrer et al.   LUNG CANCER

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion

(2018) Jung-Mao Hsu et al.   Nature Communications

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer

(2018) Manjima Dhar et al.   Scientific Reports

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer

(2018) Galatea Kallergi et al.   Therapeutic Advances in Medical Oncology

Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy

(2018) Chunyan Yue et al.   OncoImmunology

The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer

(2018) Arutha Kulasinghe et al.   Cancer Medicine

Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma

(2018) Kazuaki Chikamatsu et al.   ORAL ONCOLOGY

Characterization of single circulating tumor cells

(2017) Catherine Alix-Panabières et al.   FEBS LETTERS

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

(2017) Andreas H Scheel et al.   HISTOPATHOLOGY

A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer

(2017) Rita Lampignano et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

(2017) Leora Horn et al.   JOURNAL OF CLINICAL ONCOLOGY

Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer

(2017) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of isolation platforms for detection of circulating renal cell carcinoma cells

(2017) Yvonne Maertens et al.   Oncotarget

PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?

(2017) Cristina Raimondi et al.   OncoImmunology

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

(2017) David L. Rimm et al.   JAMA Oncology

Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer

(2016) Jakub Chudziak et al.   ANALYST

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

(2016) Archana Anantharaman et al.   BMC CANCER

Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells

(2016) Tobias M. Gorges et al.   CLINICAL CHEMISTRY

Improving the CellSearch® system

(2016) J.F. Swennenhuis et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

(2016) Pedro N Aguiar et al.   Immunotherapy

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells

(2016) G.E. Hvichia et al.   INTERNATIONAL JOURNAL OF CANCER

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

Characterization of different CTC subpopulations in non-small cell lung cancer

(2016) Annkathrin Hanssen et al.   Scientific Reports

Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients

(2016) Arun Satelli et al.   Scientific Reports

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab

(2016) Chiara Nicolazzo et al.   Scientific Reports

Frequent expression of PD-L1 on circulating breast cancer cells

(2015) Martine Mazel et al.   Molecular Oncology

Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells

(2015) Joao Paulo Oliveira-Costa et al.   Oncotarget

Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer

(2015) Annkathrin Hanssen et al.   Frontiers in Oncology

Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis

(2014) Nicola Aceto et al.   CELL

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

(2014) François-Clément Bidard et al.   LANCET ONCOLOGY

Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System

(2013) Masahito Hosokawa et al.   PLoS One

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

(2011) F Farace et al.   BRITISH JOURNAL OF CANCER

Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches

(2011) Matthew G. Krebs et al.   Journal of Thoracic Oncology

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH